9 results about "Dendritic cell vaccine" patented technology

The present disclosure belongs to the field of biotechnology, and specifically relates to a preparation method for an adenovirus p53 (Ad-p53)-loaded dendritic cell (DC) vaccine. The present disclosure includes steps of peripheral blood collection and peripheral blood mononuclear cell (PBMC) separation, PBMC sorting, DC activation, Ad-P53-transfected DC and DC vaccine preparation. P53 can be expressed on a surface of DC as a tumor-associated antigen (TAA) through DC purification, specific multiplicity of infection (MOI) and infection modes, and the Ad-P53-transfected DC has obvious antigen presentation effect, which can be used as a vaccine to activate T cells to kill tumors.

The application discloses an engineered potent dendritic cell vaccine and a preparation method and application thereof, and utilizes a nano-scale antigen delivery mode to fuse tumor antigens with cationic liposomes, destroys the stability of a lysosome membrane by means of cationic liposome charge interaction, makes part of the antigens escape into a cytoplasm to be cross-presented through an MHC I pathway, gives the DCs the ability to activate a cellular immune response to resist tumors, on the other hand, gives the DCs T cell directivity through a synthetic immunology method, promotes the interaction and signal transmission of DC-T cells, and the combination of the two mechanisms can overcome the low response rate problem of the existing DC vaccine, and maximizes the anti-tumor immune response.

The present application relates to the technical field of biomedicine, and relates to the preparation of a dendritic cell vaccine for pancreatic cancer and the use thereof in the preparation of a drug for treating pancreatic cancer. The preparation method comprises the preparation of Panc-1 and AsPC-1 lysates, the preparation of immature dendritic cells, and the preparation of a DC vaccine loaded with the Panc-1 and AsPC-1 lysates.

Methods and materials for treating cancer (e.g., ovarian cancer) using a combination of a Th 17 DC vaccine and an immune checkpoint inhibitor are provided herein.

The present application relates to the technical field of biological medicine, and more particularly to a method for screening high-activity dendritic cell vaccine by using CD39 and TIM3, which comprises the steps of sorting and / or identifying mature dendritic cells by using biomarkers CD39 and TIM3. The present application takes CD39 and TIM3 as biomarkers for sorting mo-DC, and can screen high-activity mo-DC vaccine. Experimental results show that the mo-DC vaccine obtained by using the method has high expression of biomarkers such as CD11C, HLA-DR and CD197. Meanwhile, the experimental results also show that the T cell proliferation ratio of the CD39+TIM3+DC stimulation group is significantly higher than that of the DC stimulation group, indicating that the DC sorted by using CD39 and TIM3 has strong ability to induce immune response, and is significantly higher than the mo-DC group without screening.

The application provides a preparation method of a novel dendritic cell vaccine and application thereof, and particularly discloses a method for preparing improved dendritic cells, which comprises the following steps: culturing the dendritic cells in the presence of vitamin K2, so that the dendritic cells capable of inhibiting cell death caused by tumor antigen sensitization are obtained. The improved dendritic cells can significantly enhance T cell activation and tumor cell killing ability. The application further discloses a novel method for tumor immunotherapy of the dendritic cells combined with a T cell vaccine, an existing tumor vaccine, an immune checkpoint inhibitor or radiotherapy and chemotherapy.

The present application relates to the technical field of vaccine preparation, in particular to a lentivirus dendritic cell vaccine targeting Claudin-18.2 and a preparation method and application thereof. The preparation method comprises the following steps: obtaining immature dendritic cells; using a recombinant lentivirus particle carrying a nucleotide sequence encoding a Claudin-18.2 protein to perform gene transduction on the immature dendritic cells, so that the immature dendritic cells endogenously express a Claudin-18.2 antigen; applying a maturation-promoting stimulus to the transduced dendritic cells to obtain a dendritic cell vaccine that is mature and expresses the Claudin-18.2 antigen. The vaccine can effectively induce an antigen-specific cytotoxic T lymphocyte response, is suitable for preparing a drug for treating Claudin-18.2-positive gastric cancer, and has the characteristics of strong targeting and significant immune activation effect.